natgillin/translations-raw huggingface dataset:
Luxembourg/Luxemburg LEO Pharma N.V./S.A Tél/Tel: +32 3 740 7868
LEO Pharma N.V./S.A Tél/Tel: +32 3 740 7868
Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: +32-(0)2 559 92 00
Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: + 32-(0)2 559 92 00
Luxembourg/Luxemburg ViiV Healthcare sprl/bvba Belgique/Belgien
ViiV Healthcare sprl/bvba Belgique/Belgien
LV 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
LV 400 mg/m2 intravensko 30 minut in nato 5-FU 2400 mg/m2 intravensko 46 ur, vsaka 2 tedna.
LV dose does not require adjustment.
Odmerka LV ni treba prilagajati.
LVEF 40% to
LVEF od 40 % do
LVEF = Left ventricular ejection fraction
LVEF = iztisni delež levega prekata (left ventricular ejection fraction)
lymph node pain
bolečina v bezgavkah
Lymph node pain
bolečina v bezgavki
Lymph node pain
bolečine v bezgavki
lymph node pain and swollen lymph nodes
bolečina v bezgavki in otekle bezgavke
lymph node pain; low count of white blood cells that fight infection; swollen glands in the neck, armpit and groin
bolečina v bezgavkah, nizko število belih krvnih celic, ki se borijo proti okužbi, otekle bezgavke na vratu, pod pazduho in v dimljah
Lymph node palpable Alanine aminotransferase increased
otipljiva bezgavka povečane vrednosti alanin aminotransferaze
lymph nodes enlarged (swelling under the skin of the neck, armpit or groin)
eitlastækkanir (bólga undir húð á hálsi, handarkrika eða nára)
lymph nodes enlarged (swelling under the skin of the neck, armpit or groin)
povečane bezgavke (oteklina pod kožo vratu, pazduhe ali dimelj)
Lymphadenitis
limfadenitis
Lymphadenopathy
Eitlastækkun
Lymphadenopathy (cervical, axillary)
limfadenopatija (cervikalna, aksilarna)
Lymphadenopathy (in association with hypersensitivity skin reactions)
limfadenopatija (v povezavi s preobčutljivostnimi kožnimi reakcijami)
lymphadenopathy, splenic infarction
limfadenopatija, vranični infarkt
Lymphadenopathy2, thrombocytopenia2
limfadenopatija2, trombocitopenija2
Lymphadenopathy†
limfadenopatija
lymphatic
limfatičnega
lymphatic obstruction
limfatična obstrukcija
lymphatic system
Bolezni krvi in limfatičnega sistema
lymphatic system
istema
lymphatic system
limfatičnega
lymphatic system disorders
Bolezni krvi in limfatičnega sistema
Lymphocele
limfokela
Lymphocyte count
Število limfocitov
Lymphocyte count decreased
zmanjšanje števila limfocitov
Lymphocyte count decreased
zmanjšano število limfocitov
Lymphocyte count decreased
znižano število limfocitov
Lymphocyte count decreased (<1,500/mm³) 
zmanjšano število limfocitov
Lymphocyte count decreased (NB)
zmanjšano število limfocitov (NB)
lymphocyte count decreased, white blood cell count decreased, neutrophil count decreased, hematocrit decreased, blood potassium increased, blood urea nitrogen increased
zmanjšano število limfocitov, zmanjšano število levkocitov, zmanjšano število nevrofilcev, znižan hematokrit, povečana vsebnost kalija v krvi, povečana vsebnost dušika iz sečnine v krvi
Lymphocyte counts progressively return to normal range within 1-2 months of stopping therapy (see section 5.1).
Število limfocitov se postopoma vrne v okvir normalnih vrednosti v roku 1-2 mesecev po prekinitvi zdravljenja (glejte poglavje 5.1).
lymphocytic
indrom
lymphocytic colitis),
lahko pri katerem koli
Lymphoedema
Preiskave
Lymphoedema (G3/4: 0%)
limfedem (S 3/4: 0 %)
Lymphoedema (G3/4: 0%)
Močnejše solzenje (S3/4:0,6 %)
Lymphoedema Hypertension
limfedem hipertenzija
Lymphoid tissue (e.g., tonsillar) hypertrophy associated with complications, such as snoring, sleep apnoea, and chronic middle-ear effusions have been reported with the use of INCRELEX.
Med uporabo zdravila INCRELEX so poročali o pojavu hipertrofije limfatičnega tkiva (npr. tonzilarnega) in zapletih povezanih s tem, kot so smrčanje, apneja v spanju in kronični izcedek iz srednjega ušesa.
Lymphoma – like disorder
limfomu podobna bolezen
Lymphoma*; Post transplant lympho- proliferative disorder
limfom*, potrans- plantacijska limfoproliferativ na motnja
lymphoma, solid organ tumours (including
limfom, tumorji parenhimskih organov (vključno
lymphoma, solid organ tumours (including breast, ovarian, testicular), squamous cell carcinoma of the skin
limfom, tumorji parenhimskih organov (vključno z dojkami, jajčniki in testisi), ploščatocelični karcinom
Lymphomatous meningitis is a condition in which tumour cells have invaded the fluid or membranes that surround the brain and spinal cord.
Limfomatozni meningitis je bolezen, pri kateri tumorske celice limfoma vdrejo v tekočine ali membrane, ki obdajajo možgane ali hrbtenjačo.
lymphopaenia
istema
lymphopaenia
limfopenija
Lymphopenia
limfopenija
Lymphopenia includes lymphopenia and decreased lymphocyte count. b: Hypomagnesaemia includes hypomagnesaemia and decreased blood magnesium.
Limfopenija vključuje limfopenijo in zmanjšano število limfocitov. b: Hipomagneziemija vključuje hipomagneziemijo in znižan magnezij v krvi.
Lymphopenia includes lymphopenia and lymphocyte count decreased. b: Hypomagnesaemia includes hypomagnesaemia and blood magnesium decreased.
Limfopenija vključuje limfopenijo in zmanjšano število limfocitov. b: Hipomagneziemija vključuje hipomagneziemijo in znižan magnezij v krvi.
Lymphopenia Leucopenia
limfopenija levkopenija
Lymphopenia, leukopenia
limfopenija, levkopenija
Lymphopeniab
limfope nijab
Lymphopeniac
limfopenijac
Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving CellCept (2 g or 3 g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year.
Limfoproliferativne bolezni ali limfomi so se pojavili pri 0,6 % bolnikov, ki so dobivali zdravilo CellCept (2 g ali 3 g dnevno) skupaj z drugimi imunosupresivi v nadzorovanih kliničnih preskušanjih pri bolnikih z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, ki so trajala vsaj eno leto.
lymphoproliferative disorders treatment with Xaluprine increases your risk of getting a type of cancer called lymphoproliferative disorder.
limfoproliferativne bolezni zdravljenje z zdravilom Xaluprine poveča tveganje za raka, imenovanega limfoproliferativna bolezen.
Lymphoseek 50 micrograms kit for radiopharmaceutical preparation
Lymphoseek 50 mikrogramov komplet za pripravo radiofarmaka
Lymphoseek 50 micrograms kit for radiopharmaceutical preparation
Lymphoseek 50 mikrogramov komplet za pripravo radiofarmaka tilmanocept
Lymphoseek 50 micrograms kit for radiopharmaceutical preparation Tilmanocept
Lymphoseek 50 mikrogramov komplet za pripravo radiofarmaka tilmanocept
Lymphoseek 50 micrograms solution for injection technetium (99mTc) tilmanocept
Lymphoseek 50 mikrogramov raztopina za injiciranje tehnecijev (99mTc) tilmanocept
Lymphoseek contains sodium:
Zdravilo Lymphoseek vsebuje natrij:
Lymphoseek is injected under the skin, under the nipple, or in or around the tumour.
Zdravilo Lymphoseek se injicira pod kožo, pod prsno bradavico ali v tumor ali njegovo okolico.
Lynparza can be administered in patients with mild renal impairment (creatinine clearance 51 to 80 ml/min) with no dose adjustment.
Zdravilo Lynparza se lahko pri bolnicah z blago okvaro ledvic (očistek kreatinina > 51 do 80 ml/min) uporablja brez prilagoditve odmerka.
Lynparza contains the active substance olaparib.
Zdravilo Lynparza vsebuje zdravilno učinkovino olaparib.
Lynparza dose adjustment is recommended for patients with moderate renal impairment (see section 4.2).
Pri bolnicah z zmerno okvaro ledvic se priporoča prilagoditev odmerka zdravila Lynparza (glejte poglavje 4.2).
Lynparza hard capsules contain the active substance olaparib.
Zdravilo Lynparza trde kapsule vsebuje zdravilno učinkovino olaparib.
Lynparza has been shown to increase the time patients live without their disease getting worse in one main study involving 265 patients.
V eni glavni študiji, v kateri je sodelovalo 265 bolnic, so pokazali, da je zdravilo Lynparza podaljšalo čas, ki so ga bolnice preživele brez poslabšanja bolezni.
Lynparza is a cancer medicine used for the ‘maintenance’ treatment of adult patients with high grade serous epithelial cancer of the ovary (a type of advanced cancer of the ovary), including cancer of the fallopian tubes (part of the female reproductive system that connect the ovaries to the uterus) and cancer of the peritoneum (the membrane lining the abdomen).
Zdravilo Lynparza je zdravilo proti raku, ki se uporablja za vzdrževalno zdravljenje odraslih bolnic s slabo diferenciranim seroznim epitelijskim rakom jajčnikov (vrsta napredovalega raka jajčnikov), vključno z rakom jajcevodov (del ženskega reproduktivnega sistema, ki povezuje jajčnika z maternico) in raka peritoneja (trebušne mrene).
Lynparza is given after treatment with platinum-based medicines, when the tumour is diminishing in size or has completely disappeared.
Zdravilo Lynparza se daje po zdravljenju z zdravili na osnovi platine, kadar se tumor zmanjšuje ali je popolnoma izginil.
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Zdravilo Lynparza je kot monoterapija indicirano za vzdrževalno zdravljenje odraslih bolnic z mutacijo gena BRCA (germinalno ali somatsko) pri katerih je prišlo do ponovitve slabo diferenciranega seroznega epitelijskega raka jajčnikov, karcinoma jajcevodov in primarno peritonealnega karcinoma, občutljivega na platino, ki so v popolnem ali delnem odzivu na kemoterapijo na osnovi platine.
Lynparza is not recommended for use in patients with severe renal impairment or end-stage renal disease (creatinine clearance ≤ 30 ml/min) since there are no data in such patients.
Ker ni podatkov o uporabi zdravila Lynparza pri bolnicah s hudo okvaro ledvic ali končno odpovedjo ledvic (očistek kreatinina ≤ 30 ml/min), se uporabe zdravila Lynparza pri teh bolnicah ne priporoča.
Lynparza is used in patients who have mutations (defects) in one of the two genes known as BRCA1 and BRCA2 and who have recurrent disease (when the cancer has come back after previous treatment).
Zdravilo Lynparza se uporablja pri bolnicah z mutacijami (okvarami) enega od dveh genov, imenovanih BRCA1 in BRCA2, pri katerih se je bolezen ponovila (rak se je po predhodnem zdravljenju ponovno pojavil).
Lynparza may influence your ability to drive and use machines.
Zdravilo Lynparza lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Lynparza may only be used in patients with severe renal impairment if the benefit outweighs the potential risk, and the patient should be carefully monitored for renal function and adverse events.
Zdravilo Lynparza se sme pri bolnicah s hudo okvaro ledvic uporabiti le, če koristi odtehtajo možna tveganja; bolnicam je potrebno skrbno spremljati delovanje ledvic in neželene učinke.
Lynparza should be taken at least one hour after food and patients should not eat preferably for up to two hours afterwards.
Zdravilo Lynparza je treba vzeti vsaj eno uro po obroku, bolnice pa naj ne bi jedle še dve uri po tem.
Lynparza should not be used during pregnancy and in women of childbearing potential not using reliable contraception during therapy and for 1 month after receiving the last dose of Lynparza (see section 4.6).
Zdravila Lynparza se ne sme uporabljati med nosečnostjo ali pri ženskah v rodni dobi, ki ne uporabljajo zanesljive kontracepcije med zdravljenjem in še en mesec po prejetju zadnjega odmerka zdravila Lynparza (glejte poglavje 4.6).
Lynparza was given not later than 8 weeks after the last cycle of platinum-based medicines, when the tumour was diminishing in size or had completely disappeared.
Bolnice so zdravilo Lynparza prejele najkasneje 8 tednov po zadnjem ciklu zdravil na osnovi platine, kadar se je tumor zmanjševal oziroma je popolnoma izginil.
LYOPHILISATE
LIOFILIZAT
Lyophilisate
Liofilizat za suspenzijo
lyophilisate
liofilizata
Lyophilisate (live attenuated)
Liofilizat (živi atenuirani):
Lyophilisate (live attenuated) Minimum Maximum
Liofilizat (živi atenuirani) Najmanj Največ
Lyophilisate (live attenuated) Minimum Maximum
Liofilizat (živi atenuirani): Najmanj Največ
Lyophilisate (white lyophilisate) Active substance:
Liofilizat (bel liofilizat) Zdravilna učinkovina:
Lyophilisate + solvent for suspension for injection
liofilizat + vehikel za suspenzijo za injiciranje
Lyophilisate : white pellet.
Liofilizat: bel pelet
Lyophilisate and
Liofilizat in
Lyophilisate and solvent for oculonasal suspension
Liofilizat in topilo za okulo- nazalno suspenzijo
Lyophilisate and solvent for solution for injection
liofilizat in vehikel za raztopino za injiciranje
Lyophilisate and solvent for suspension
Liofilizat in topilo za suspenzijo
Lyophilisate and solvent for suspension for injection
Liofilizat in topilo - vbrizgljiva suspenzija
Lyophilisate and solvent for suspension for injection
Liofilizat in topilo za raztopino za injiciranje.
Lyophilisate and solvent for suspension for injection
Liofilizat in topilo za suspenzijo za injiciranje
Lyophilisate and solvent for suspension for injection
Liofilizat in vehikel za suspenzijo za injiciranje za pse
Lyophilisate and solvent for suspension for injection
Liofilizat in vehikel za suspenzijo za injiciranje.
lyophilisate and solvent for suspension for injection for cats
liofilizat in vehikel za suspenzijo za injiciranje za mačke
Lyophilisate and solvent for suspension for injection.
Liofilizat in vehihel za suspenzijo za injiciranje.
Lyophilisate and solvent for suspension for injection.
Liofilizat in vehihel –suspenzija za injiciranje
Lyophilisate and solvent for suspension for injection.
Liofilizat in vehikel –suspenzija za injiciranje.
Lyophilisate and solvent for suspension for injection.
Prašek in vehikel za suspenzijo za injiciranje.
Lyophilisate and solvent for suspension..
Liofilizat in vehikel za suspenzijo
Lyophilisate bottle
Steklenička liofilizata
Lyophilisate bottle
Steklenička z liofilizatom
Lyophilisate CUPS
MERICE z liofilizatom
Lyophilisate for oral suspension
Liofilizat za peroralno suspenzijo
lyophilisate for oral suspension for pigs
liofilizat za peroralno suspenzijo za prašiče
Lyophilisate for suspension
Liofilizat za suspenzijo
Lyophilisate for suspension for injection
liofilizat in vehikel za suspenzijo za injiciranje
Lyophilisate for suspension for spray
Liofilizat za suspenzijo za pršilo
Lyophilisate for suspension for spray vaccination and for use in drinking water
Liofilizat za suspenzijo za cepljenje s pršenjem ali za dajanje v vodo za pitje
Lyophilisate vial
Viala z liofilizatom
LYOPHILISATE VIAL LABEL
NALEPKA ZA VIALO Z LIOFILIZATOM
Lyophilisate vial label (10 and 50 doses)
Viala (10 in 50 odmerekov liofilizata)
Lyophilisate VIALS
VIALE z liofilizatom
Lyophilisate vials: 5 doses, 10 doses and 25 doses
Viale z liofilizatom: 5 odmerkov, 10 odmerkov in 25 odmerkov
Lyophilisate vials: 50 doses
Viale z liofilizatom: 50 odmerkov
Lyophilisate: 1 dose;
Liofilizat:
Lyophilisate: 1 dose; solvent: 0.8 ml
1 odmerek; vehikel: 0,8 ml
Lyophilisate: 1 vial; solvent:
liofilizat: 1 viala; vehikel:
Lyophilisate: 1 vial; solvent: 1 vial
Liofilizat: 1 viala; vehikel: 1 viala
Lyophilisate: 1 vials; solvent:
liofilizat: 1 viala; vehikel:
Lyophilisate: 10 doses, solvent:
10 odmerkov, vehikel:
Lyophilisate: 10 vials; solvent:
liofilizat: 10 vial; vehikel:
Lyophilisate: 25 doses, solvent:
25 odmerkov, vehikel:
Lyophilisate: 4 vials; solvent:
liofilizat: 4 viale; vehikel:
Lyophilisate: 5 doses, solvent:
5 odmerkov, vehikel:
Lyophilisate: 5 doses; solvent: 10 ml
Liofilizat: 5 odmerki; vehikel: 10 ml
Lyophilisate: 5 vials; Solvent: 5 vials
5 vial + 5 vial
Lyophilisate: 50 doses, solvent:
50 odmerkov, vehikel:
Lyophilisate: 57 months (4 years and 9 months)
Liofilizat: 57 mesecev (4 leta in 9 mesecev)
Lyophilisate: 6 vials; solvent:
liofilizat: 6 vial; vehikel:
Lyophilisate: 6 x 1 dose
Liofilizat 6 x 1 odmerek
Lyophilisate: bottle (type I glass); solvent: bottle (type I glass or PET)
Liofilizat: steklenička (tipa I stekla); vehikel: steklenička (tipa I stekla ali PET)
Lyophilisate: bottle (type I glass); solvent: bottle (type II glass or PET)
Liofilizat: steklenička (tipa I stekla); vehikel: steklenička (tipa II stekla ali PET)
Lyophilisate: bromobutyl rubber stoppers and aluminium caps
Liofilizat: zamaški iz brombutilne gume in aluminijaste zaporke
Lyophilisate: cup (Alu/PP); Solvent: vial (LDPE)
Topilo: viala (LDPE)
Lyophilisate: Off white, predominantly sphere shaped.
Liofilizat: belkast, večinoma v obliki kroglic
Lyophilisate: off-white or cream coloured pellet Solvent: clear colourless solution
Liofilizat: peleta belkaste ali krem barve Vehikel: bistra brezbarvna raztopina
Lyophilisate: off-white or cream-coloured pellet Solvent: clear colourless solution
Liofilizat: peleta belkaste ali krem barve Vehikel: bistra brezbarvna raztopina
Lyophilisate: Off-white pellet
Liofilizat: pelet bele do belkaste barve
Lyophilisate: spongy matter of white colour
Liofilizat: spužvasta snov bele barve.
Lyophilisate: spongy matter of white colour.
Liofilizat: bela porozna snov
Lyophilisate: spongy matter of white colour.
Liofilizat: bela porozna snov.
Lyophilisate: spongy matter of white colour.
Liofilizat: spužvasta snov bele barve.
Lyophilisate: Store and transport refrigerated (2 °C – 8 °C).
Liofilizat: Shranjujte in prevažajte v hladilniku (2 ºC – 8 ºC)
Lyophilisate: Store in a refrigerator (2 C – 8 C).
Liofilizat: Shranjujte v hladilniku (2 C–8 C).
Lyophilisate: Store in a refrigerator (2 C – 8 C).
Liofilizat: Shranjujte v hladilniku (2C – 8C).
Lyophilisate: Sucrose Glycine Glutamic acid
Liofilizat: Saharoza Glicin
Lyophilisate: Trometamol Edetic Acid Sucrose Dextran 70
Liofilizat: Trometamol Saharoza Edetna kislina Dekstran 70
Lyophilisate: vial (glass); Solvent: bottle (HDPE)
liofilizat: viala (steklo); vehikel: steklenica (HDPE)
Lyophilisate: vial (glass); solvent: vial (glass)
liofilizat: viala (stekla); vehikel: viala (stekla)
Lyophilised formulation of palivizumab
Palivizumab v liofilizirani obliki
Lyophilised HIB component: Lactose
Komponenta HIB v liofiliziranem stanju: laktoza
Lyophilised powder: 340 mg
Liofiliziran prašek: 340 mg
Lyophilised powder: 852 mg
Liofiliziran prašek: 852 mg
Lyophilised powder: Do not store above 25C.
Liofiliziran prašek: Shranjujte pri temperaturi do 25 C.
Lyrica 100 mg hard capsules EU/1/04/279/014-016 EU/1/04/279/39
Lyrica 100 mg trde kapsule EU/1/04/279/014-016 EU/1/04/279/039
Lyrica 20 mg/ml oral solution
Lyrica 20 mg/ml peroralna raztopina
Lyrica 200 mg hard capsules EU/1/04/279/020 – 022 EU/1/04/279/041
Lyrica 200 mg trde kapsule EU/1/04/279/020-022 EU/1/04/279/041
Lyrica 225 mg hard capsules EU/1/04/279/033 – 035 EU/1/04/279/042
Lyrica 225 mg trde kapsule EU/1/04/279/033-035 EU/1/04/279/042
Lyrica 25 mg hard capsules EU/1/04/279/001-005 EU/1/04/279/026 EU/1/04/279/036
Lyrica 25 mg trde kapsule EU/1/04/279/001-005 EU/1/04/279/026 EU/1/04/279/036
Lyrica 300 mg hard capsules EU/1/04/279/023 – 025 EU/1/04/279/029 EU/1/04/279/032 EU/1/04/279/043
Lyrica 300 mg trde kapsule EU/1/04/279/023-025 EU/1/04/279/029 EU/1/04/279/032 EU/1/04/279/043
Lyrica 50 mg hard capsules EU/1/04/279/006-010 EU/1/04/279/037
Lyrica 50 mg trde kapsule EU/1/04/279/006-010 EU/1/04/279/037
Lyrica 75 mg hard capsules EU/1/04/279/011-013 EU/1/04/279/027 EU/1/04/279/030 EU/1/04/279/038 EU/1/04/279/045
Lyrica 75 mg trde kapsule EU/1/04/279/011-013 EU/1/04/279/027 EU/1/04/279/030 EU/1/04/279/038 EU/1/04/279/045
Lyrica capsules may be taken with or without food.
Kapsule Lyrica lahko jemljete s hrano ali brez nje.
Lyrica has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients.
Zdravljenje z zdravilom Lyrica lahko spremljata omotica in zaspanost, ki lahko pri starejših bolnikih zvečata pogostnost nezgodnih poškodb (padcev).
Lyrica is for oral use only.
Zdravilo Lyrica je namenjeno le za peroralno uporabo.
Lyrica is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Zdravilo Lyrica je indicirano za zdravljenje generalizirane anksiozne motnje (GAD - Generalised Anxiety Disorder) pri odraslih.
Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.
Zdravilo Lyrica je indicirano za zdravljenje periferne in centralne nevropatske bolečine pri odraslih.
Lyrica is used as an ‘add-on’ to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).
Zdravilo Lyrica se uporablja kot dodatek k obstoječim zdravljenjem pri bolnikih s parcialnimi napadi (epileptični napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem; splošno anksiozno motnjo (dolgotrajno anksioznostjo ali živčnostjo zaradi vsakdanjih stvari).
Lyrica may be taken with or without food.
Zdravilo Lyrica lahko jemljete s hrano ali brez nje.
Lyrica may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
Uporaba zdravila Lyrica lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
Lyrica may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.
Zdravilo Lyrica lahko povzroči omotico in somnolenco in tako lahko vpliva na sposobnost vožnje in upravljanja s stroji.
Lyrica may have minor or moderate influence on the ability to drive and use machines.
Zdravilo Lyrica ima lahko blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Lyrica may produce dizziness, sleepiness and decreased concentration.
Zdravilo Lyrica lahko povzroči omotico, zaspanost in poslabša sposobnost koncentracije.
Lyrica oral solution contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).
Zdravilo Lyrica peroralna raztopina vsebuje metilparahidroksibenzoat in propilparahidroksibenzoat, ki lahko povzročita alergijske reakcije (lahko zapoznele).
Lyrica with food, drink and alcohol
Zdravilo Lyrica skupaj s hrano, pijačo in alkoholom
Lysodren has a major influence on the ability to drive and use machines.
Lysodren ima velik vpliv na sposobnost vožnje in upravljanja s stroji.
Lysodren has a major influence on your ability to drive and use machines.
Zdravilo Lysodren ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
LYSODREN PATIENT CARD
LYSODREN – IZKAZNICA BOLNIKA
Lyxumia 10 mcg injection lixisenatide
Lyxumia 10 mcg injekcija liksisenatid
Lyxumia 10 micrograms solution for injection
Lyxumia 10 mikrogramov raztopina za injiciranje
Lyxumia 10 micrograms solution for injection is available for the starting dose.
Za začetni odmerek zdravljenja je na voljo Lyxumia 10 mcg raztopina za injiciranje.
Lyxumia 10 micrograms solution for injection lixisenatide
Lyxumia 10 mikrogramov raztopina za injiciranje liksisenatid
Lyxumia 10 micrograms solution for injection Lyxumia 20 micrograms solution for injection
Lyxumia 10 mikrogramov raztopina za injiciranje Lyxumia 20 mikrogramov raztopina za injiciranje
Lyxumia 20 mcg injection lixisenatide
Lyxumia 20 mcg injekcija liksisenatid
Lyxumia 20 micrograms solution for injection is available for the maintenance dose.
Za vzdrževalni odmerek je na voljo Lyxumia 20 mikrogramov raztopina za injiciranje.
Lyxumia 20 micrograms solution for injection lixisenatide
Lyxumia 20 mikrogramov raztopina za injiciranje liksisenatid
Lyxumia can be used with 29 to 32 gauge disposable pen needles.
Zdravilo Lyxumia je mogoče uporabiti z iglami za peresnik za enkratno uporabo številke 29 do 32.